Page last updated: 2024-12-10

sb 225002

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3854666
CHEMBL ID239767
CHEBI ID93074
SCHEMBL ID1110610
MeSH IDM0289850

Synonyms (47)

Synonym
HMS3269P11
BRD-K61323504-001-01-6
gtpl833
3-(2-bromophenyl)-1-(2-hydroxy-4-nitrophenyl)urea
HSCI1_000088
sb-225002
sb225002
sb 225002 ,
NCGC00167841-01
n-(2-hydroxy-4-nitrophenyl)-n'-(2-bromophenyl)urea
CHEMBL239767 ,
AKOS001571729
L000539
EC-000.2439
bdbm50203012
1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea
n-(2-bromophenyl)-n'-(2-hydroxy-4-nitrophenyl)urea
182498-32-4
S7651
ES-0015
CS-3538
MQBZVUNNWUIPMK-UHFFFAOYSA-N
SCHEMBL1110610
AC-32729
HY-16711
B6055
HMS3648O06
DTXSID20397383
CHEBI:93074
J-011676
EX-A2754
1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea.
mfcd00954637
SY231254
HMS3677D14
Q27088712
SR-01000946394-1
sr-01000946394
BCP11852
HMS3413D14
BRD-K61323504-001-03-2
A14209
urea, n-(2-bromophenyl)-n'-(2-hydroxy-4-nitrophenyl)-
AC1209
HMS3742G17
CCG-268049
A921036
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitrophenolAny member of the class of phenols or substituted phenols carrying at least 1 nitro group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-X-C chemokine receptor type 1Homo sapiens (human)IC50 (µMol)1.51100.00102.022710.0000AID707880; AID707881
C-X-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)0.06230.00000.30296.0130AID1166111; AID1166121; AID1811229; AID306084; AID707879
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
dendritic cell chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 1Homo sapiens (human)
immune responseC-X-C chemokine receptor type 1Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 1Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-X-C chemokine receptor type 2Homo sapiens (human)
signal transductionC-X-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cell population proliferationC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil activationC-X-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 2Homo sapiens (human)
immune responseC-X-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
interleukin-8 receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
nucleoplasmC-X-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 2Homo sapiens (human)
microtubule cytoskeletonC-X-C chemokine receptor type 2Homo sapiens (human)
membraneC-X-C chemokine receptor type 2Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 2Homo sapiens (human)
mast cell granuleC-X-C chemokine receptor type 2Homo sapiens (human)
mitotic spindleC-X-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID452857Antagonist activity at CXCR2 expressed in 7w CHO cells co-expressing human recombinant APP 751 assessed as inhibition of gamma-secretase-mediated amyloid beta42 production2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
AID1811216Antimigratory activity against human MDA-MB-231 cells assessed as reduction in cell migration at 2 uM measured after 24 hrs by crystal violet staining based transwell assay relative to control2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811225Inhibition of epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as downregulation of vimentin expression at 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811226Inhibition of epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as downregulation of beta-catenin expression at 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811217Anti-angiogenesis activity in HUVEC cells assessed as reduction in blood vessel area at 2 uM measured after 12 hrs by inverted microscopic analysis relative to control2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811224Inhibition of epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as downregulation of fibronectin expression at 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1166111Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
AID1811215Antimigratory activity against human MDA-MB-231 cells assessed as reduction in cell migration at 2 uM measured after 24 hrs by wound healing assay relative to control2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811227Down-regulation of VEGF expression in HUVEC cells assessed as 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID707880Binding affinity to CXCR12012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID1811228Induction of ROS production in human human MDA-MB-231 cells assessed as increase in mean fluorescence intensity at 10 uM measured after 24 hrs by DCFH-DA staining based inverted microscopic analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID306084Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.
AID707881Antagonist activity at CXCR1 assessed as inhibition of CXCL8 binding by cell based assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID452859Antagonist activity at CXCR2 expressed in 7w CHO cells assessed as inhibition of GROalpha-mediated intracellular calcium mobilization by Fura-4 NW fluorescence assay2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
AID1528085Antitumor activity against human SKOV3 cells xenografted in athymic Nu/Nu mouse assessed as reduction in tumor volume at 10 mg/kg/day, ip co-treated with sorafenib 30 mg/kg, po relative to sorafenib alone2020European journal of medicinal chemistry, Jan-01, Volume: 185Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead.
AID1811223Inhibition of epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as upregulation of E-cadherin expression at 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID306085Selectivity for human CXCR2 over human CXCR12007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.
AID707879Binding affinity to CXCR22012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID1166121Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
AID1811229Antagonist activity against CXCR2 (unknown origin) by calcium flux assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346826Human CXCR2 (Chemokine receptors)1998The Journal of biological chemistry, Apr-24, Volume: 273, Issue:17
Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (92)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.09)18.2507
2000's15 (16.30)29.6817
2010's49 (53.26)24.3611
2020's27 (29.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.25 (24.57)
Research Supply Index4.53 (2.92)
Research Growth Index5.60 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other90 (97.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]